

Short Name	Comments	Type	Investigator	Contact
Disease site specific				
Mesothelioma				
	None			
Unresectable 1st line				
	None			
Surgical and Adjuvant				
Roche GO29527	A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In PD-L1- Selected Patients With Completely Resected Stage IB- IIIA Non-Small Cell Lung Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CP-MGA271-03	Macrogenics Protocol CP-MGA271-03: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
Alliance 151216	Non-Squamous, Large IB, II or IIIA, any EGFR/ALK, Resected. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (<i>ALCHEMIST</i>) For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
E4512	Must be enrolled in A151216. NSCLC; ALK+; Surgically Resected Early Stage. <i>Crizotinib/Placebo</i> For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA5142	Must be enrolled in A151216. Randomized Phase III Study of Nivoumab After Surgical Resection and Adjuvant chemotherapy in Non-Small Cell Lung Cancers For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Alliance A081105	Must be enrolled in A151216. NSCLC; EGFR Mutant, Resected Tumor.Treatment <u>Erlotinib/Placebo</u>	Treatment	<u>CRCWM Physician Investigators</u>	CRCWM (616) 391-1230 <u>www.crcwm.org</u>
<u>For More Information</u>				
Roche GO29527	A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In PD-L1- Selected Patients With Completely Resected Stage IB- IIIA Non-Small Cell Lung Cancer	Treatment	<u>CRCWM Physician Investigators</u>	CRCWM (616) 391-1230 <u>www.crcwm.org</u>
<u>For More Information</u>				
SWOG S1206	A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)	Treatment	<u>CRCWM Physician Investigators</u>	CRCWM (616) 391-1230 <u>www.crcwm.org</u>
<u>For More Information</u>				
Stage IV or Recurrent				
CP-MGA271-03	Macrogenics Protocol CP-MGA271-03: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers	Treatment	<u>START Midwest Investigators</u>	START Midwest (616) 954-5554
EA5162	Phase II study of AZD9291 (Osimertinib) advanced NSCLC Patients with Exon 20 Insertion	Treatment	<u>CRCWM Physician Investigators</u>	CRCWM (616) 391-1230 <u>www.crcwm.org</u>

SWOG S1400 LUNG MAP	Squamous Cell Lung; A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study); S14001 <i>Nivolumab</i> plus <i>Ipilimumab</i> versus Nivolumab for Patients with No Matching Biomarker For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
SWOG S1403	NSCLC/ EGFR mut+; Stage IV or Recurrent 1st line. Treatment-Naïve; Phase II/III; Treatment: <i>Afatinib</i> Plus <i>Cetuximab</i> Versus <i>Afatinib</i> Alone For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG LU002	Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
<i>Small-cell Lung</i>				
CALGB 30610	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Astra Zeneca D419QC00001	Astra Zeneca D419QC00001 A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)	Treatment	Chen, Yuanbin	CHCWM (616) 954-9800 www.chcwm.com

Protocols that are NOT disease site specific

Treatment

Alexion ALXN6000-ONC-102	Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ALEXO AT148001	Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

BGB-290	A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
SCI-CD47-001	First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
MK-4280-001	A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
LZM009-001	A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ASN002	A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
20150195 AMG 820	A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
R3767-ONC- 1613	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CP-MGA012-01	A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

MK-4820	A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ASN003-101	A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
MK-8353-013	A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
5F9004	A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CP-MGA012-01	A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CVM-001	A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
APX_CLN_0011	A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CPI-1205-202	A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

NRG CC003	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
NRG CC001	A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
A071401	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
Molecular Profiling				
QOL Multisite EAQ-152	EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - MATCH	MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131	Dasatinib in Patients with Tumors with DDR2 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			

EAY131 - A	Solid Tumors (Other than SC & NSCLC) or Lymphomas; <u>Afatinib</u> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - B	Tumors with HER2 Activating Mutations; Treatment: <u>Afatinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - C1	<u>Crizotinib</u> in Patients with Tumors with MET Amplification	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - C2	<u>Crizotinib</u> in Patients with Tumors with MET Exon 14 Deletion	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - E	Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u>AZD9291</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - F	Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u>Crizotinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - G	ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u>Crizotinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

EAY131 - J	<i>Trametinib</i> and <i>Pertuzumab</i> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - L	Phase II Study of MLN0128 (<i>TAK-228</i>) in Patients with Tumors with mTOR Mutations For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - M	Phase II Study of MLN0128 (<i>TAK-228</i>) in Patients with Tumors with TSC1 or TSC2 Mutations For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - R	BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <i>Trametinib</i> For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - S1	<i>Trametinib</i> in Patients with Tumors with NF1 Mutations For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - S2	<i>Trametinib</i> in Patients with Tumors with GNAQ or GNA 11 Mutations For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131 - T	Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <i>GDC-0449 (vismodegib)</i> For More Information	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

EAY131 - V	Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - W	Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - X	<u>Dasatinib</u> in Patients with Tumors with DDR2 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Y	<u>AZD5363</u> in Patients with Tumors with AKT Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1A	<u>Binimetinib</u> in Patients with Tumors (Other than Melanoma) with NRAS Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1B	MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1D	<u>Nivolumab</u> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

EAY131 - Z1E	Testing <i>LOXO-101</i> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes		CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - Z1I	Testing <i>AZD1775</i> as a Possible Treatment in People who have Cancer with BRCA Mutations		CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
ASCO TAPUR	Targeted Agent and Profiling Utilization Registry Study. <i>All drugs provided</i>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
Biorepository				
NCI PDM 9846	Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)	Biobanking	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
SHARE	The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators	Biobanking	Cottingham, Sandra	Spectrum Health Biorepository david.chesla@spectrumhealth.org (616) 267-2629
	<i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i>			
Assessment/ Education				
URCC 13059 GAP-70	Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults	Other	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			

Symptom Management

S1415CD	A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) For More Information	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 04040 YOCAS	A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors For More Information	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 16070	Treatment of Refractory Nausea For More Information	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org